Author

A. Ibanez-Costa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:statistical model· 1

Frequent Co-Authors

E. Alors-Perez· 2 shared J. P. Castano· 2 shared M. D. Gahete· 2 shared R. Blazquez-Encinas· 2 shared R. M. Luque· 2 shared S. Pedraza-Arevalo· 2 shared A. Arjona-Sanchez· 1 shared A. C. Fuentes-Fayos· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Alors-Perez

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in Pancreatic Ductal Adenocarcinoma

R. Blazquez-Encinas, E. Alors-Perez, M. T. Moreno-Montilla, V. Garcia-Vioque, M. E. Sanchez-Frias, A. Mafficini, J. L. Lopez-Canovas, C. Bousquet, M. D. Gahete, R. T. Lawlor, R. M. Luque, A. Scarpa, A. Arjona-Sanchez, S. Pedraza-Arevalo, A. Ibanez-Costa, J. P. Castano

This study identifies EIF4A3 as an oncogenic factor in PDAC by showing its overexpression correlates with poor prognosis and its role in regulating RNA splicing and tumor growth.

bioRxiv · Dec 7, 2023Cancer Biology

Spliceosomic dysregulation unveils NOVA1 as an actionable therapeutic target in pancreatic neuroendocrine tumors

S. Pedraza-Arevalo, E. Alors-Perez, R. Blazquez-Encinas, A. D. Herrera-Martinez, J. M. Jimenez-Vacas, A. C. Fuentes-Fayos, O. Reyes, S. Ventura, R. Sanchez-Sanchez, R. Ortega-Salas, R. Serrano-Blanch, M. A. Galvez-Moreno, M. D. Gahete, A. Ibanez-Costa, R. M. Luque, J. P. Castano

The paper identifies NOVA1 as a therapeutic target in PanNETs by showing its role in splicing dysregulation, cell proliferation, and drug resistance.

bioRxiv · Feb 9, 2022 · PreprintCancer Biology